RTRX (How many shares will the index need to buy??)
Retrophin Announces Addition to the NASDAQ Biotechnology Index
Business Wire Retrophin, Inc.
RETROPHIN, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T EDGAR Online 15 hrs ago
Ousted Retrophin CEO Sold Stock While Urging Investors to Buy TheStreet q 20 days ago
More
NEW YORK--(BUSINESS WIRE)--
Retrophin, Inc. (RTRX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. In order for companies to be eligible for inclusion on this list, companies must have a minimum market cap of $200 million and a minimum daily trading volume of 100,000 shares. For more information about the NASDAQ Biotechnology Index, please visit www.nasdaq.com.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Thiola® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, infantile spasms, nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes
